Poverty and Profit in the American City” (2016), which won the Pulitzer Prize for General Nonfiction. Here’s what The New York Times had to say about both books: What made his previous book, ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent ...

Actor Patricia Clarkson talks about her latest film “Lilly,” where she plays Lilly Ledbetter, the tire factory worker who fought for equal pay. She discusses Ledbetter's legacy in history and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other the Stock That Will Make You Rich in 5-10 Years. The US economy grew by 3% in the ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global portfolio If Medicare were to start covering popular weight loss drugs such as ...

Image provided by The Outlier. South Africa. A road trip through five of South Africa's provinces, exploring the risks and opportunities of the transition to cleaner energy. To view the complete ...

Many of the top recommendations in our best mattress of the year guide are on sale this October too, including the Saatva Classic, our number one pick. Today you can save 15% on orders worth $ ...

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the drug makes it through to ...

Black Friday deals are near as we head closer to the November date. Thanks to Amazon's October Prime Day sale, which just wrapped up, we should see early sales popping up in the coming weeks.

PT101 is an engineered IL-2 mutein fused to a protein backbone, and is vying to come to market along with other IL-2-based therapies, notably Eli Lilly and Nektar Therapeutics’ phase 2 candidate ...